Glass containers with improved strength and improved damage tolerance

Patent metadata

Field	Value
Publication number	US-2019084875-A1
Application number	US-201816185819-A
Country	US
Kind code	A1
Filing date	Nov 9, 2018
Priority date	Nov 30, 2012
Publication date	Mar 21, 2019
Grant date	—

Abstract

Glass pharmaceutical packages comprising glass containers are disclosed. In embodiments, a coated glass pharmaceutical package includes a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A lubricous coating may be positioned on at least a portion of the exterior surface of the glass container. The portion of the coated glass pharmaceutical package with the lubricous coating has a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package. A horizontal compression strength of the portion of the coated glass pharmaceutical package with the lubricous coating may be at least 10% greater than an uncoated glass pharmaceutical package.

First claim

What is claimed is:

1 . A coated glass pharmaceutical package comprising:
a glass container having an interior surface and an exterior surface and a wall extending therebetween, wherein the glass container is formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard; and a lubricous coating having a thickness of ≤100 microns positioned on at least a portion of the exterior surface, wherein:
the portion of the exterior surface of the coated glass pharmaceutical package with the lubricous coating has a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle; and
a horizontal compression strength of the portion of the exterior surface of the coated glass pharmaceutical package with the lubricous coating is at least 10% greater than an uncoated glass pharmaceutical package and the horizontal compression strength is not reduced by more than 20% after undergoing the depyrogenation cycle.

2 . The coated glass pharmaceutical package of claim 1 , wherein the lubricous coating is thermally stable at a temperature of at least about 280° C. for 30 minutes.

3 . The coated glass pharmaceutical package of claim 1 , wherein at least the interior surface of the glass container has a delamination factor less than or equal to 10.

4 . The coated glass pharmaceutical package of claim 1 , wherein the lubricous coating is an inorganic coating comprising at least one of a metal nitride coating, a metal oxide coating, a metal sulfide coating, SiO 2 , diamond-like carbon graphenes, or a carbide coating.

5 . The coated glass pharmaceutical package of claim 4 , wherein the inorganic coating comprises at least one of TiN, BN, hBN, TiO 2 , Ta 2 O 5 , HfO 2 , Nb 2 O 5 , V 2 O 5 , SiO 2 , MoS 2 , SiC, SnO, SnO 2 , ZrO 2 , Al 2 O 3 , ZnO, or BC.

6 . The coated glass pharmaceutical package of claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≤0.7.

7 . The coated glass pharmaceutical package of claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≤0.6.

8 . The coated glass pharmaceutical package of claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≤0.5.

9 . The coated glass pharmaceutical package of claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≤0.4.

10 . The coated glass pharmaceutical package of claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≤0.3.

11 . The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises heating the coated glass pharmaceutical package to a temperature of at least 250° C. for at least 30 minutes.

12 . The coated glass pharmaceutical package of claim 1 , wherein a light transmission through the coated glass pharmaceutical package is greater than or equal to about 55% of a light transmission through an uncoated glass pharmaceutical package for each wavelength from about 400 nm to about 700 nm after undergoing the depyrogenation cycle.

13 . The coated glass pharmaceutical package of claim 1 , wherein the lubricous coating comprises a polymer.

14 . The coated glass pharmaceutical package of claim 13 , wherein the lubricous coating further comprises a coupling agent.

15 . The coated glass pharmaceutical package of claim 14 , wherein the coupling agent is in direct contact with the exterior surface of the glass container and the polymer is in direct contact with the coupling agent.

16 . The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises heating the coated glass pharmaceutical package to a temperature of at least 260° C. for at least 30 minutes.

17 . The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises heating the coated glass pharmaceutical package to a temperature of from about 250° C. to about 400° C. for a time period of at least 30 minutes.

18 . The coated glass pharmaceutical package of claim 1 , wherein a light transmission through the portion of the exterior surface of the coated glass pharmaceutical package with the lubricous coating is greater than or equal to about 55% of a light transmission through an uncoated glass pharmaceutical package for each wavelength from about 400 nm to about 700 nm after the depyrogenation cycle.

19 . The coated glass pharmaceutical package of claim 18 , wherein the depyrogenation cycle comprises heating the coated glass pharmaceutical package in air at a temperature of at least about 250° C. for 30 minutes and the coated glass pharmaceutical package is thermally stable after the depyrogenation cycle.

20 . The coated glass pharmaceutical package of claim 17 , wherein the glass container has at least a class S3 acid resistance or better according to DIN 12116.

Assignees

• Corning Inc

Inventors

• Chang Theresa
• Danielson Paul Stephen
• Demartino Steven Edward
• Fadeev Andrei Gennadyevich
• Morena Robert Michael
• Pal Santona
• Peanasky John Stephen
• Schaut Robert Anthony
• Timmons Christopher Lee
• Venkataraman Natesan
• Verkleeren Ronald Luce

Classifications

• C03C17/22

  with other inorganic material (C03C17/34, C03C17/44 take precedence) · CPC title

• A61J1/065

  Rigid ampoules, e.g. glass ampoules · CPC title

• B65D1/42

  Reinforcing or strengthening parts or members · CPC title

• B65D23/0821

  consisting mainly of polymeric materials (B65D23/0828 takes precedence) · CPC title

• B65D1/0215

  multilayered (B65D81/3837 takes precedence) · CPC title